In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.

Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies. Some cheap stocks are owned by businesses in high-growth sectors that are profiting from long-term structural trends, but not all of them are a good deal. Finding these chances, however, necessitates negotiating a volatile macroeconomic landscape.

One of the defining themes of 2026 has been the conflict in the Middle East. On June 15, Reuters reported in its article, “Iran deal could expand market gains, with consumer shares, small caps seen benefiting,” that easing geopolitical tensions and lower oil prices could boost consumer spending while reducing inflationary pressures and Treasury yields. As a result, economically sensitive sectors such as consumer stocks, small-cap companies, and energy-dependent markets were expected to benefit, potentially broadening market leadership beyond AI-driven technology stocks. JPMorgan strategists noted,

“If our positive macro view plays out – underpinned by strong earnings, stable inflation expectations, and an easing of geopolitical risks in the second half – cyclicals should remain well positioned to outperform through year-end.”

However, doubt was rekindled on June 20 when Reuters reported that Iran had closed the Strait of Hormuz due to suspected ceasefire violations.

Many analysts continue to be optimistic about stocks in spite of these dangers. Sébastien Page, T. Rowe Price Head of Global Multi-Asset & CIO, told CNBC on May 13 that historic market highs are not trustworthy sell signals, pointing out that expected S&P 500 profits growth increased from 13% at the end of March to 27%. His firm continues to favor US large-cap growth stocks, citing attractive valuations and strong AI-driven earnings. Meanwhile, on May 12, Chris Veronne of Strategas cautioned that weakness in banks and consumer stocks deserves close attention, though the lack of a significant rotation into defensive sectors such as consumer staples and healthcare suggests investors have not yet turned broadly risk-averse.

With that said, let’s now take a look at the best low-price pharma stocks.

Our Methodology

For our methodology, we screened for pharmaceutical stocks priced below $50, based on the last close price as of June 24, with positive analyst upside. From this universe, we selected the 10 stocks with the most recent news and developments and ranked them in ascending order based on the number of hedge funds holding each stock as of Q1 2026, according to Insider Monkey’s database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Here is our list of the 12 best low-priced pharma stocks to buy right now.

12. Medicus Pharma Ltd. (NASDAQ:MDCX)

Number of Hedge Fund Holders: 4

Stock Price: $0.42

Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation request with the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.

The submission follows the company’s previously filed Orphan Drug Designation application and ongoing FDA review of its registrational study design. MDCX reported that recent Phase 2 results demonstrated encouraging clinical and complete response rates while maintaining a favorable safety profile. If granted, the designation could support the company’s regulatory strategy and potentially provide eligibility for a Rare Pediatric Disease Priority Review Voucher, subject to future FDA approval.

Separately, Medicus Pharma Ltd. (NASDAQ:MDCX) announced earlier on June 8 that it had filed a substantial modification application through the European Union CTIS for the planned Phase 2b study of Teverelix in advanced prostate cancer. The study is intended to refine dose selection while further evaluating the therapy’s pharmacokinetics, pharmacodynamics, efficacy, and safety before registrational development. The program is focused on patients with elevated cardiovascular risk who require androgen deprivation therapy and builds on the company’s previous regulatory discussions with the FDA regarding its clinical development strategy for advanced prostate cancer.

Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotechnology company focused on advancing early-stage therapeutic candidates through clinical development and partnering with larger pharmaceutical companies for commercialization.

11. High Tide Inc. (NASDAQ:HITI)

Number of Hedge Fund Holders: 9

Stock Price: $2.21

High Tide Inc. (NASDAQ:HITI) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that HITI reported record second-quarter fiscal 2026 financial results. The corporation reported that its revenue increased 30% year over year to $179.3 million, while gross profit climbed 36% to $48.4 million, with gross margin improving to 27%. Adjusted EBITDA reached a record $13.9 million, up 73% from the prior year, and income from operations rose 554% to $6.1 million. The company also generated $1.5 million in free cash flow and reported positive net income. Meanwhile, Cabana Club membership surpassed 2.65 million, and the Canna Cabana retail network expanded to 221 stores across Canada.

Additionally, on the same day, High Tide Inc. (NASDAQ:HITI) entered into a definitive agreement to acquire 100% of J. Supply Holdings Inc., operating as Northern Helm, in a transaction valued at $7.74 million. The deal includes four cannabis retail stores in Ontario and is expected to expand the company’s Canna Cabana network to 228 locations nationwide, including 103 stores in Ontario. The acquisition consideration consists of approximately $3.2 million in assumed debt, about $1.83 million in cash, and roughly $2.75 million in High Tide common shares. The purchase price represents 4.5x the stores’ annualized adjusted EBITDA.

High Tide Inc. (NASDAQ:HITI) is a cannabis company operating retail, e-commerce, and medical distribution businesses. As Canada’s largest cannabis retailer, it is expanding internationally, including into Germany’s medical cannabis market.